Introduction: Diazoxide is the first line and only Federal Drug Agency approved pharmacological agent for the treatment of hyperinsulinism. Its use has increased over the years to include patients with various genetic forms of hyperinsulinism, perinatal stress hyperinsulinism and infants of diabetic mothers with more babies than ever being exposed to this therapy. Methods: We performed a retrospective analysis of 194 patients with hyperinsulinism in our clinic and looked for those who had experienced serious adverse events (SAE) including pulmonary hypertension and neutropenia. We compared the rates of SAE in the different types of hyperinsulinism. Results: Out of 194 patients with hyperinsulinism, 165 (85.1%) were treated with diazoxide. There were 17 SAEs in 16 patients including 8 cases of pulmonary hypertension and 8 of neutropenia. These data show that overall the frequency of SAE associated with diazoxide use is 9.7%, but that those with perinatal stress hyperinsulinism have a much higher rate than those with genetic forms of hyperinsulinism (16.7 vs. 3.6%; p = 0.01). We also found diazoxide is associated with pulmonary hypertension (4.8% of patients treated). Although more patients with perinatal stress hyperinsulinism (7.6%) were affected than genetic hyperinsulinism (1.2%), the difference was not significant (p = 0.088). Conclusion: The rate of SAEs associated with (not necessarily caused by) diazoxide has been demonstrated. The rate of SAE in newborns with perinatal stress hyperinsulinism is significantly higher than that of otherwise healthy babies with genetic forms of hyperinsulinism, suggesting that caution should be used when prescribing diazoxide to this population. This information should help balance the risk benefit of treatment and provide guidance on screening for these complications in the population of treated patients.

1.
Menni
F
,
de Lonlay
P
,
Sevin
C
,
Touati
G
,
Peigné
C
,
Barbier
V
, et al.
Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia
.
Pediatrics
.
2001
Mar
;
107
(
3
):
476
9
.
[PubMed]
0031-4005
2.
Steinkrauss
L
,
Lipman
TH
,
Hendell
CD
,
Gerdes
M
,
Thornton
PS
,
Stanley
CA
.
Effects of hypoglycemia on developmental outcome in children with congenital hyperinsulinism
.
J Pediatr Nurs
.
2005
Apr
;
20
(
2
):
109
18
.
[PubMed]
0882-5963
3.
Bindu Avatapalle
H
,
Banerjee
I
,
Shah
S
,
Pryce
M
,
Nicholson
J
,
Rigby
L
, et al.
Abnormal neurodevelopmental outcomes are common in children with transient congenital hyperinsulinism
.
Front Endocrinol
.
2013
;
4
(
60
):
1
6
. 1124-1292
4.
Helleskov
A
,
Melikyan
M
,
Globa
E
,
Shcherderkina
I
,
Poertner
F
,
Larsen
AM
, et al.
Both Low Blood Glucose and Insufficient Treatment Confer Risk of Neurodevelopmental Impairment in Congenital Hyperinsulinism: A Multinational Cohort Study
.
Front Endocrinol (Lausanne)
.
2017
Jul
;
8
:
156
.
[PubMed]
1664-2392
5.
Hoe
FM
,
Thornton
PS
,
Wanner
LA
,
Steinkrauss
L
,
Simmons
RA
,
Stanley
CA
.
Clinical features and insulin regulation in infants with a syndrome of prolonged neonatal hyperinsulinism
.
J Pediatr
.
2006
Feb
;
148
(
2
):
207
12
.
[PubMed]
0022-3476
6.
Weinzimer
SA
,
Stanley
CA
,
Berry
GT
,
Yudkoff
M
,
Tuchman
M
,
Thornton
PS
.
A syndrome of congenital hyperinsulinism and hyperammonemia
.
J Pediatr
.
1997
Apr
;
130
(
4
):
661
4
.
[PubMed]
0022-3476
7.
Glaser
B
,
Thornton
P
,
Otonkoski
T
,
Junien
C
.
Genetics of neonatal hyperinsulinism
.
Arch Dis Child Fetal Neonatal Ed
.
2000
Mar
;
82
(
2
):
F79
86
.
[PubMed]
1359-2998
8.
Calabria
AC
,
Gallagher
PR
,
Simmons
R
,
Blinman
T
,
De León
DD
.
Postoperative surveillance and detection of postprandial hypoglycemia after fundoplasty in children
.
J Pediatr
.
2011
Oct
;
159
(
4
):
597
601.e1
.
[PubMed]
0022-3476
9.
Drash
A
,
Wolff
F
.
Drug therapy in leucine-sensitive hypoglycemia
.
Metabolism
.
1964
Jun
;
13
(
6
):
487
92
.
[PubMed]
0026-0495
10.
Lundvall
O
,
Johnsson
S
.
Insulinoma treated with diazoxide
.
Nord Med
.
1965
Jan
;
73
:
53
6
.
[PubMed]
0029-1420
11.
Samols
E
,
Marks
V
.
Hyperinsulinism Due to Metastasizing Insulinoma—treatment with Diazoxide
.
Proceedings of the Association of Clinical Biochemists.
1965
;
3
(
7
):
260
1
.
12.
Drash
A
,
Kenny
F
,
Field
J
,
Blizzard
R
,
Langs
H
,
Wolff
F
.
The therapeutic application of diazoxide in pediatric hypoglycemic states
.
Ann N Y Acad Sci
.
1968
Apr
;
150
(
2
):
337
55
.
[PubMed]
0077-8923
13.
National Library of Medicine
. DaileyMed. [Package insert]. Proglycem-diazoxide suspension.
2018
March 19. Available from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b16c7832-2fd9-49af-b923-1dc0d91fd6e2
14.
Kizu
R
,
Nishimura
K
,
Sato
R
,
Kosaki
K
,
Tanaka
T
,
Tanigawara
Y
, et al.
Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia
.
Horm Res Paediatr
.
2017
;
88
(
5
):
316
23
.
[PubMed]
1663-2818
15.
Tas
E
,
Mahmood
B
,
Garibaldi
L
,
Sperling
M
.
Liver injury may increase the risk of diazoxide toxicity: a case report
.
Eur J Pediatr
.
2015
Mar
;
174
(
3
):
403
6
.
[PubMed]
0340-6199
16.
Snider
KE
,
Becker
S
,
Boyajian
L
,
Shyng
SL
,
MacMullen
C
,
Hughes
N
, et al.
Genotype and phenotype correlations in 417 children with congenital hyperinsulinism
.
J Clin Endocrinol Metab
.
2013
Feb
;
98
(
2
):
E355
63
.
[PubMed]
0021-972X
17.
US Food and Drug Administration
. FDA Drug Safety Podcast: FDA warns about a serious lung condition in infants and newborns treated with Proglycem (diazoxide).
2015
July 16. Available from https://www.fda.gov/Drugs/DrugSafety/ucm454833.htm
18.
Gray
KD
,
Dudash
K
,
Escobar
C
,
Freel
C
,
Harrison
T
,
McMillan
C
, et al.;
Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee
.
Prevalence and safety of diazoxide in the neonatal intensive care unit
.
J Perinatol
.
2018
Nov
;
38
(
11
):
1496
502
.;
Epub ahead of print
.
[PubMed]
0743-8346
19.
Herrera
A
,
Vajravelu
ME
,
Givler
S
,
Mitteer
L
,
Avitabile
CM
,
Lord
K
, et al.
Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide
.
J Clin Endocrinol Metab
.
2018
Dec
;
103
(
12
):
4365
72
.
[PubMed]
0021-972X
20.
Welters
A
,
Lerch
C
,
Kummer
S
,
Marquard
J
,
Salgin
B
,
Mayatepek
E
, et al.
Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers
.
Orphanet J Rare Dis
.
2015
Nov
;
10
(
1
):
150
.
[PubMed]
1750-1172
21.
Bhatt
V
,
Saleem
A
.
Review: drug-induced neutropenia—pathophysiology, clinical features, and management
.
Ann Clin Lab Sci
.
2004
;
34
(
2
):
131
7
.
[PubMed]
0091-7370
22.
Timlin
MR
,
Black
AB
,
Delaney
HM
,
Matos
RI
,
Percival
CS
.
Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review
.
Pediatr Cardiol
.
2017
Aug
;
38
(
6
):
1247
50
.
[PubMed]
0172-0643
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.